Lybalvi (Olanzapine/Samidorphan Malate) Patent Expiration, LOE Window & CMS Spending
Lybalvi (Olanzapine/Samidorphan Malate) by Alkermes: FDA Orange Book core substance LOE 2031-08-30 (last listed 2041-11-12), 0 AB generics, $284.6M 2024 CMS Part D & Medicaid spend.
| Regulatory & Reimbursement Dimension | Verified Value |
|---|---|
| Consolidated Sponsor | Alkermes |
| FDA Application & Pathway | N213378 (NDA) |
| Exclusivity / Cliff Horizon | Long-Dated Protection (2036+) |
| Core Active-Ingredient LOE Date | 2031-08-30 |
| Last Listed Patent or Exclusivity Date | 2041-11-12 |
| Orange Book Patents (*PED Extensions) | 14 patents (0 *PED) |
| Active AB-Rated Generic Competitors | 0 |
| 2024 CMS Total Public Spend | $284.6M |
| 2024 Medicare Part D Spend | $127.3M |
| 2024 Medicaid Spend | $157.3M |
| Reported Wholesale Price Change (CA SB 17) | 0 statutory filings in 2023 to 2026 panel |
Related Filings Across Meru Platforms
Verified cross-ledger federal filings for Alkermes across sibling Meru public-data platforms.